Establishing organoid models carrying FGF19/FGFR4 mutations can also be used to evaluate the antitumor effects of relevant inhibitors and provide insights into the role of the FGF19/FGFR4 pathway in tumor resistance mechanisms, thereby offering new ideas and strategies for overcoming drug resistance. Here, FGF19 is linked to neoplasm.